2 reports of this reaction
8.3% of all Trelegy reports
#2 most reported adverse reaction
HOSPICE CARE is the #2 most commonly reported adverse reaction for Trelegy, manufactured by Aurobindo Pharma Limited. There are 2 FDA adverse event reports linking Trelegy to HOSPICE CARE. This represents approximately 8.3% of all 24 adverse event reports for this drug.
Patients taking Trelegy who experience hospice care should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOSPICE CARE is moderately reported among Trelegy users, representing a notable but not dominant share of adverse events.
In addition to hospice care, the following adverse reactions have been reported for Trelegy:
HOSPICE CARE has been reported as an adverse event in 2 FDA reports for Trelegy. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOSPICE CARE accounts for approximately 8.3% of all adverse event reports for Trelegy, making it one of the most commonly reported side effect.
If you experience hospice care while taking Trelegy, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.